CTLA4 and ovarian cancer: A similar observation has been reported in a model of ovarian cancer in which therapeutic co-blockade of PD-1/LAG-3/CTLA-4 in WT mice leads to two times fewer tumor free mice compared to anti-LAG-3/CTLA-4 treatment in PD-1-/- mice (20).